Lytix Biopharma AS
OSE:LYTIX
Lytix Biopharma AS
EPS (Diluted)
Lytix Biopharma AS
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
EPS (Diluted)
kr0
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
B
|
Bergenbio ASA
OSE:BGBIO
|
EPS (Diluted)
-kr3
|
CAGR 3-Years
54%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
EPS (Diluted)
kr0
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
EPS (Diluted)
$0
|
CAGR 3-Years
-59%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
EPS (Diluted)
kr0
|
CAGR 3-Years
66%
|
CAGR 5-Years
53%
|
CAGR 10-Years
26%
|
|
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
See Also
What is Lytix Biopharma AS's EPS (Diluted)?
EPS (Diluted)
-1.7
NOK
Based on the financial report for Dec 31, 2024, Lytix Biopharma AS's EPS (Diluted) amounts to -1.7 NOK.
What is Lytix Biopharma AS's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-15%
Over the last year, the EPS (Diluted) growth was 19%. The average annual EPS (Diluted) growth rates for Lytix Biopharma AS have been -12% over the past three years , -15% over the past five years .
You don't have any saved screeners yet